Table 2 Distribution of characteristics in patients with intermediate survival prognoses
8 Gy × 1 N patients (%) | 4 Gy × 5 N patients (%) | |
|---|---|---|
Age | ||
≤65 years (N = 30) | 15 (35) | 15 (35) |
≥66 years (N = 56) | 28 (65) | 28 (65) |
Gender | ||
Female (N = 26) | 13 (30) | 13 (30) |
Male (N = 60) | 30 (70) | 30 (70) |
ECOG Performance status | ||
1–2 (N = 32) | 16 (37) | 16 (37) |
3–4 (N = 54) | 27 (63) | 27 (63) |
Type of primary tumor | ||
Breast cancer (N = 12) | 6 (14) | 6 (14) |
Prostate cancer (N = 34) | 17 (40) | 17 (40) |
Myeloma/lymphoma (N = 4) | 2 (5) | 2 (5) |
Lung cancer (N = 12) | 6 (14) | 6 (14) |
Unknown primary (N = 4) | 2 (5) | 2 (5) |
Other tumors (N = 20) | 10 (23) | 10 (23) |
Involved vertebrae (n) | ||
1–2 (N = 34) | 17 (40) | 17 (40) |
≥3 (N = 52) | 26 (60) | 26 (60) |
Other bone metastases | ||
No (N = 34) | 17 (40) | 17 (40) |
Yes (N = 52) | 26 (60) | 26 (60) |
Visceral metastases | ||
No (N = 50) | 25 (58) | 25 (58) |
Yes (N = 36) | 18 (42) | 18 (42) |
Interval from tumor diagnosis to MESCC | ||
≤ 15 months (N = 44) | 22 (51) | 22 (51) |
> 15 months (N = 42) | 21 (49) | 21 (49) |
Pre-RT ambulatory status | ||
Not ambulatory (N = 44) | 22 (51) | 22 (51) |
Ambulatory (N = 42) | 21 (49) | 21 (49) |
Time developing motor deficits | ||
1–7 days (N = 24) | 12 (28) | 12 (28) |
8–14 days (N = 24) | 12 (28) | 12 (28) |
> 14 days (N = 38) | 19 (44) | 19 (44) |